People · Operator
Named in public records as an officer, director or promoter · active 2014–2025 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Moderna LLC | — | Pharmaceuticals | Growth/Late | $691.1M | $16.2B | 2014 |
| Moderna Therapeutics, Inc. | — | Biotechnology | Growth/Late | $451.4M | $19.2B | 2016 |
| ADARx Pharmaceuticals, Inc. | — | Pharmaceuticals | Series D+ | $352.5M | $2.8B | 2023 |
| Triana Biomedicines, Inc. | — | Pharmaceuticals | Series D+ | $178.6M | $852.1M | 2025 |
| Abata Therapeutics, Inc. | — | Biotechnology | Series C | $60.3M | $168.4M | 2021 |
Lorence Kim at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Lorence Kim on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Langer | 2 | 36 |
| Shelley Chu | 2 | 10 |
| Noubar Afeyan | 2 | 9 |
| Lee Babiss | 2 | 5 |
| PETER HUTT | 2 | 4 |
| Stephane Bancel | 2 | 4 |
| John Mendlein | 2 | 4 |
| Henri Termeer | 2 | 3 |
| Carl Gordon | 1 | 24 |
| ANDREW LEVIN | 1 | 17 |
| Joshua Resnick | 1 | 12 |
| Simeon George | 1 | 8 |
| Christopher O'Donnell | 1 | 8 |
| Judith Li | 1 | 8 |
| Chen Yu | 1 | 7 |
| Erez Chimovits | 1 | 7 |
| David Kaufman | 1 | 7 |
| ABBIE CELNIKER | 1 | 6 |
| David Grayzel | 1 | 6 |
| Robert Carpenter | 1 | 5 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.